{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:53:13Z","timestamp":1780987993469,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.semnuclmed.2022.10.003","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T08:50:34Z","timestamp":1667551834000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Molecular Imaging of Lymphoma: Future Directions and Perspectives"],"prefix":"10.1053","volume":"53","author":[{"given":"Kelsey L.","family":"Pomykala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ophir","family":"Vermesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0001","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.seminhematol.2018.05.007","article-title":"Diagnosis and classification of lymphoma: Impact of technical advances","volume":"56","author":"Jaffe","year":"2019","journal-title":"Semin Hematol"},{"issue":"420","key":"10.1053\/j.semnuclmed.2022.10.003_bib0002","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0003","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11912-021-01127-6","article-title":"Current role of functional imaging in the management of lymphoma","volume":"23","author":"Cheson","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0004","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.1996.14.9.2427","article-title":"Role of image-guided core-needle biopsy in the management of patients with lymphoma","volume":"14","author":"Pappa","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0005","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: An overview","volume":"102","author":"Sabattini","year":"2010","journal-title":"Pathologica"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0006","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0007","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","article-title":"Role of functional imaging in the management of lymphoma","volume":"29","author":"Cheson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0008","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11307-009-0259-3","article-title":"On the added value of baseline FDG-PET in malignant lymphoma","volume":"12","author":"Quarles van Ufford","year":"2010","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0009","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1259\/bjr\/31542964","article-title":"Spleen in haematological malignancies: Spectrum of imaging findings","volume":"85","author":"Saboo","year":"2012","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0010","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0011","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.112.114710","article-title":"In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET\/CT provides better diagnostic performance and prognostic stratification than does biopsy","volume":"54","author":"Berthet","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0012","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2012-12-473389","article-title":"PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement","volume":"122","author":"Khan","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0013","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: Guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"23","author":"Barajas","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0014","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/neuonc\/noaa030","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases","volume":"22","author":"Kaufmann","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3174\/ajnr.A1750","article-title":"Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma","volume":"31","author":"Barajas","year":"2010","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0016","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/RLU.0000000000003404","article-title":"Assessment of central nervous system lymphoma based on CXCR4 expression in vivo using 68Ga-Pentixafor PET\/MRI","volume":"46","author":"Starzer","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0017","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0018","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(20)30357-4","article-title":"The role of PET in first-line treatment of Hodgkin lymphoma","volume":"8","author":"Trotman","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0019","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1182\/blood-2010-10-314260","article-title":"Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I\/II nonbulky Hodgkin lymphoma: Pretreatment prognostic factors and interim PET","volume":"117","author":"Straus","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0020","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0021","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ajh.24169","article-title":"Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET\/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0022","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11899-010-0062-x","article-title":"Prognostic markers in peripheral T-cell lymphoma","volume":"5","author":"Piccaluga","year":"2010","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0023","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","article-title":"Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma","volume":"3","author":"Mehta-Shah","year":"2019","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0024","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","article-title":"The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)","volume":"25","author":"Luminari","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0025","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(20)30365-3","article-title":"The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma","volume":"8","author":"Barrington","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0026","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on interim-PET scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leukemia & Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0027","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin Lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"JCO"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0028","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/jpm11030217","article-title":"Early evaluation of immunotherapy response in lymphoma patients by 18F-FDG PET\/CT: A literature overview","volume":"11","author":"Ferrari","year":"2021","journal-title":"JPM"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0029","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0030","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","article-title":"Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-Cell Lymphoma: SUV-based assessment versus visual analysis","volume":"48","author":"Lin","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0031","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2967\/jnumed.120.244145","article-title":"Interim PET evaluation in diffuse large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the \u0394SUV max method","volume":"62","author":"Rekowski","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0032","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1080\/10428194.2021.1948028","article-title":"End-of-treatment 18F-FDG PET\/CT in diffuse large B cell lymphoma patients: \u0394SUV outperforms Deauville score","volume":"62","author":"Allioux","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0033","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood.2019003277","article-title":"Prognostic value of interim FDG-PET in diffuse large cell lymphoma: Results from the CALGB 50303 clinical trial","volume":"135","author":"Sch\u00f6der","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0034","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1080\/10428194.2020.1855341","article-title":"SUV max -based assessment of PET response shows a superior specificity to Deauville criteria for predicting recurrence in Hodgkin's lymphoma","volume":"62","author":"Texte","year":"2021","journal-title":"Leukemia & Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0035","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12885-021-08225-5","article-title":"The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: A population-based study showing improved outcome","volume":"21","author":"Noring","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0036","unstructured":"Seifert R, Kersting D, Rischpler C, et al.: Interim FDG-PET Analysis to Identify Patients with Aggressive Non-Hodgkin lymphoma who benefit from treatment intensification: A post-hoc analysis of the PETAL Trial. Leukemia Accepted for publication."},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0037","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: A simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"JH","year":"2016","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0038","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00259-014-2715-9","article-title":"qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma","volume":"41","author":"Hasenclever","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0039","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1007\/s00259-014-2879-3","article-title":"Interim FDG PET scans in lymphoma: SUV measurement error may impair qPET methodology","volume":"41","author":"Laffon","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0040","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2967\/jnumed.120.255034","article-title":"Interim PET in diffuse large B-Cell Lymphoma","volume":"62","author":"Kurch","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0041","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2967\/jnumed.118.210047","article-title":"Metabolic tumor volume for response prediction in advanced-stage Hodgkin lymphoma","volume":"60","author":"Mettler","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0042","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","author":"Kanoun","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0043","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","article-title":"Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation","volume":"131","author":"Akhtari","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0044","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0045","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1200\/JCO.21.02063","article-title":"Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International Metabolic Prognostic Index","volume":"40","author":"Mikhaeel","year":"2022","journal-title":"JCO"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0046","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1148\/radiol.2019191114","article-title":"18 F-FDG PET\/CT uptake classification in lymphoma and lung cancer by using deep convolutional neural networks","volume":"294","author":"Sibille","year":"2020","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0047","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1007\/s00259-021-05270-x","article-title":"Just another \u201cClever Hans\u201d? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer","volume":"48","author":"Weber","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0048","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.120.242412","article-title":"Deep-learning 18 F-FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-Cell lymphoma","volume":"62","author":"Capobianco","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0049","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","article-title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT\u2020","volume":"32","author":"Cottereau","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0050","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1148\/radiol.2015150689","article-title":"Diffuse large B-cell lymphoma: Prospective multicenter comparison of early interim FLT PET\/CT versus FDG PET\/CT with IHP, EORTC, Deauville, and PERCIST criteria for early therapeutic monitoring","volume":"280","author":"Minamimoto","year":"2016","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0051","doi-asserted-by":"crossref","first-page":"690","DOI":"10.2967\/jnumed.110.084566","article-title":"Predictive value of initial 18 F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment","volume":"52","author":"Herrmann","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0052","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13550-021-00776-9","article-title":"Angiogenesis imaging study using interim [18F] RGD-K5 PET\/CT in patients with lymphoma undergoing chemotherapy: Preliminary evidence","volume":"11","author":"Tonnelet","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0053","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2967\/jnumed.117.206920","article-title":"18 F-Fludarabine PET for lymphoma imaging: First-in-humans study on DLBCL and CLL patients","volume":"59","author":"Chantepie","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0054","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.7150\/thno.26754","article-title":"[18 F]Fludarabine-PET as a promising tool for differentiating CNS lymphoma and glioblastoma: Comparative analysis with [18 F]FDG in human xenograft models","volume":"8","author":"Hovhannisyan","year":"2018","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0055","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.3390\/cancers14153814","article-title":"The role of [68Ga]Ga-Pentixafor PET\/CT or PET\/MRI in lymphoma: A systematic review","volume":"14","author":"Albano","year":"2022","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0056","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.120.257279","article-title":"Improved primary staging of marginal-zone lymphoma by addition of CXCR4-directed PET\/CT","volume":"62","author":"Duell","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0057","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood.2021013239","article-title":"CXCR4 PET\/MRI for follow-up of gastric mucosa\u2013associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication","volume":"139","author":"Mayerhoefer","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.003_bib0058","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2967\/jnumed.121.262134","article-title":"Detecting fibroblast activation proteins in lymphoma using 68 Ga-FAPI PET\/CT","volume":"63","author":"Jin","year":"2022","journal-title":"J Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:40:59Z","timestamp":1757544059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299822000903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0001299822000903"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.10.003","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Imaging of Lymphoma: Future Directions and Perspectives","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}